Advertisement

Advertisement

colorectal cancer

Van K. Morris, MD, on Colon Cancer: ctDNA as a Predictive Biomarker

Van K. Morris, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results on using circulating tumor DNA (ctDNA) as a predictive biomarker of adjuvant chemotherapy in patients with stage II colon cancer. During the trial, no improvement in ctDNA clearance was observed after 6 months of chemotherapy following resection of disease. Dr. Morris notes that future trials should account for evolving assay performance in patients with colorectal cancer (Abstract 5).

Colorectal Cancer
Supportive Care

Study Finds Majority of Patients With Lynch Syndrome Are Not Using Aspirin to Reduce Risk of Colon Cancer

Investigators have found that only a minority of patients with Lynch syndrome may be receiving aspirin as chemopreventive therapy, according to new findings presented by Singhal et al at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract 19). Background “[Patients] with Lynch syndrome are...

Colorectal Cancer

First-Line Nivolumab Plus Ipilimumab Shows Benefit in Metastatic Colorectal Cancer Subset

In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer derived significant benefit from an immunotherapy doublet of nivolumab plus ipilimumab in the first-line setting, which...

Colorectal Cancer

Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?

Following surgery to remove a colorectal tumor, patients may have molecular measurable residual disease (MRD). Circulating tumor DNA (ctDNA), or liquid biopsy, may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from...

Colorectal Cancer

Role of Postoperative ctDNA in Patients With Low-Risk Stage IIA Colon Cancer

The role of circulating tumor DNA (ctDNA), or liquid biopsy, as a predictive tool to guide and monitor cancer treatment remains unclear, after the first prospective randomized phase II trial evaluating clearance of ctDNA in patients with stage II colon cancer receiving adjuvant chemotherapy did not ...

Colorectal Cancer

Addition of Cetuximab Maintenance to First-Line FOLFIRI/Cetuximab in RAS/BRAF Wild-Type Colorectal Cancer

As reported in the Journal of Clinical Oncology by Pinto et al, the Italian phase III ERMES trial showed that the addition of cetuximab maintenance to eight cycles of first-line FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus cetuximab did not achieve noninferiority in terms of...

Colorectal Cancer
Issues in Oncology

Combating Racial and Ethnic Disparities in Precision Medicine for Colorectal Cancer

Investigators may have uncovered molecular evidence of racial disparities in the receipt of precision medicine, according to a recent study published by Yamada et al in npj Precision Oncology. Background Colorectal cancer is the third most common cancer type diagnosed in both male and female...

Colorectal Cancer

Addition of MRI to CT in Patients Scheduled for Colorectal Liver Metastases Local Therapy

In the European CAMINO study reported in The Lancet Oncology, Görgec et al identified the likelihood of change in treatment plans with the addition of contrast-enhanced magnetic resonance imaging (MRI) in patients scheduled for local therapy for colorectal liver metastases on the basis of...

Pancreatic Cancer
Colorectal Cancer
Issues in Oncology

Novel Vaccine May Delay Relapse in KRAS-Mutated Pancreatic and Colorectal Cancers

A novel vaccine may be effective at preventing relapse in patients with KRAS-mutated pancreatic and colorectal cancers, according to a recent study published by Pant et al in Nature Medicine. Background KRAS-mutated cancers make up about 25% of all solid tumors, including 90% of pancreatic cancer...

Colorectal Cancer

Non–Locally Advanced Rectal Cancer: Impact of Reduced Use of Neoadjuvant Radiotherapy

In a Dutch nationwide cross-sectional cohort study reported in JAMA Oncology, Hazen et al found that a reduced use of neoadjuvant radiotherapy as part of chemoradiotherapy was not associated with poorer outcomes in patients with non–locally advanced rectal cancer. As stated by the investigators,...

Colorectal Cancer
Issues in Oncology

Comparing Outcomes of Robotic and Laparoscopic Surgeries for Colorectal Cancer

Robotic surgery may offer significant benefits over laparoscopic procedures in patients with colorectal cancer undergoing colectomies, according to a recent study published by Farah et al in the World Journal of Surgical Oncology. These findings suggest that a majority of patients receiving robotic ...

Immunotherapy
Colorectal Cancer
Gynecologic Cancers

Next-Generation Sequencing May Help Improve Access to Immunotherapy Among Patients With Cancer and Mismatch Repair Deficiency

Next-generation sequencing may help better identify patients with cancer and mismatch repair deficiency who may benefit from immunotherapy, according to a recent study published by Farhat et al in Cancer Cell. The new findings indicated that treating more patients with immunotherapy may require...

Colorectal Cancer
Immunotherapy

Can Immunotherapy Induce Sustained Disease Control Among Patients With Colorectal Cancer?

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, and the third-leading cause of cancer-related deaths. According to the American Cancer Society, in 2023, it is estimated that about 52,550 individuals died from the...

Colorectal Cancer
Genomics/Genetics

DNA Mutational Profiling in Patients With Metastatic Colorectal Cancer

As reported in the Journal of Clinical Oncology by Innocenti et al, analysis of DNA mutational profiling in the phase III CALGB (Alliance)/SWOG 80405 trial of patients with metastatic colorectal cancer treated with bevacizumab or cetuximab with chemotherapy showed differences in outcome associated...

Colorectal Cancer
Issues in Oncology

GLP-1 Receptor Agonists May Reduce Risk of Colorectal Cancer in Patients With High BMI and Diabetes

Glucagon-like peptide 1 (GLP-1) receptor agonists may be effective at reducing the risk of colorectal cancer in patients with a higher body mass index (BMI) and diabetes, according to a recent study published by Wang et al in JAMA Oncology. Background Obesity is a chronic health condition that...

Colorectal Cancer
Survivorship
Supportive Care

Consuming Navy Beans May Improve Gut Health, Regulate Immune and Inflammatory Processes in Colorectal Cancer Survivors

Researchers have uncovered that the regular consumption of navy beans may help modulate markers linked to obesity and disease and improve the gut microbiome in colorectal cancer survivors, according to a novel study published by Zhang et al in eBioMedicine. Background Obesity, poor diet, and...

Colorectal Cancer

Colorectal Cancer: Incidence and Time to Recurrence

In a nationwide Danish cohort study reported in JAMA Oncology, Nors et al found the 5-year risk of recurrence after surgery for stage I to III colorectal cancer decreased over time and the time to recurrence was shorter with a more advanced disease stage. Study Details The study used the Danish...

Colorectal Cancer
Survivorship

Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors

In a European study reported in the Journal of Clinical Oncology, Heymer et al found that the risk of subsequent colorectal cancer was elevated among childhood cancer survivors who had undergone abdominopelvic radiotherapy. Study Details The study used data from the PanCareSurFup Study—a...

Colorectal Cancer

CodeBreaK 300: Sotorasib Plus Panitumumab of Benefit in KRAS-Mutated Metastatic Colorectal Cancer

The combination of sotorasib and panitumumab significantly improved progression-free survival compared with standard treatment in patients with chemotherapy-refractory metastatic colorectal cancer with KRAS G12C mutations, the phase III CodeBreaK 300 trial has shown. The KRAS G12C inhibitor...

Colorectal Cancer
Issues in Oncology

Lack of Basic Care in Patients With Colorectal Cancer in Sub-Saharan Africa

A high proportion of patients with colorectal cancer in Sub-Saharan Africa may receive no treatment or inadequate treatment, regardless of the disease’s curability, according to a recent study published by Hämmerl et al in JNCCN–Journal of the National Comprehensive Cancer Network. The new findings ...

Colorectal Cancer

Prevalence of Unsatisfactory Samples From FIT Tests for Colorectal Cancer Screening

A retrospective cohort study by Liu et al published in Cancer Epidemiology, Biomarkers & Prevention investigated the prevalence and reasons for an unsatisfactory fecal immunochemical test (FIT). Researchers found that over 10% of the tests used for routine colorectal cancer screening contained...

Colorectal Cancer

Addition of Adjuvant HIPEC to Standard Chemotherapy in Locally Advanced Colon Cancer

As reported in the Journal of Clinical Oncology by Zwanenburg et al, 5-year findings from the Dutch COLOPEC trial indicated that the addition of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) to systemic chemotherapy did not improve overall survival vs chemotherapy alone in patients...

Colorectal Cancer

Racial Disparities in Guideline-Concordant Care in Early-Onset Colorectal Cancer in the United States

In a study reported in the Journal of Clinical Oncology, Nogueira et al found that among U.S. Black and White patients with early-onset colorectal cancer, Black patients were more likely to receive poorer and less timely care. As stated by the investigators: “Young individuals racialized as Black...

Colorectal Cancer

Long-Term Organ Preservation With Total Neoadjuvant Therapy in Rectal Adenocarcinoma

In a 5-year follow-up of the phase II OPRA trial reported in the Journal of Clinical Oncology, Verheij et al found that many patients receiving total neoadjuvant therapy for rectal adenocarcinoma remained free of the need for total mesorectal excision. Study Details In the U.S. multicenter trial,...

Colorectal Cancer
Issues in Oncology

Cancer Care Disparities Among Patients With Early-Onset Colorectal Cancer

Investigators have found that Black patients with early-onset colorectal cancer in the United States may receive worse and less timely, guideline-concordant care than White patients, according to a recent study published by Nogueira et al in the Journal of Clinical Oncology. Background “Colorectal...

Colorectal Cancer

FDA Approves Fruquintinib for Refractory Metastatic Colorectal Cancer

On November 8, the U.S. Food and Drug Administration (FDA) approved fruquintinib (Fruzaqla) for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy; and—if their disease is RAS wild-type and it...

Colorectal Cancer

Having Colorectal Cancer at 32 Changed the Trajectory of My Life

I’ve been contending with health issues since I was 12, when I was diagnosed with Crohn’s disease. As I began my early 30s, I was feeling the healthiest of my life. I was working out 5 days a week and attributed sudden weight loss and fatigue to weight training and high-intensity Zumba classes....

Colorectal Cancer
Issues in Oncology

Personalized Care May Prevent Overscreening for Colorectal Cancer in Older Patients

Researchers have found that presenting older patients with personalized information regarding the benefits and harms of colorectal cancer screenings may reduce unnecessary screenings, according to a recent study published by Saini et al in JAMA Internal Medicine. Background Colorectal cancer...

Breast Cancer
Colorectal Cancer
Gynecologic Cancers
Issues in Oncology

Insurance Coverage Disruptions May Reduce Rate of Cancer Screenings

Investigators have found that U.S. adult patients with prior insurance coverage disruptions may be less likely to receive guideline-concordant and past-year cancer screenings compared with those with continuous coverage, according to new findings presented by Shi et al at the 2023 ASCO Quality Care ...

Colorectal Cancer

Sotorasib Plus Panitumumab in KRAS G12C–Mutated Advanced Colorectal Cancer: CodeBreaK 300

The phase III CodeBreaK 300 trial showed that sotorasib plus panitumumab improved progression-free survival vs standard care in patients with KRAS G12C–mutated refractory metastatic colorectal cancer. Findings were presented at the European Society for Medical Oncology (ESMO) Congress 2023 (LBA10)...

Colorectal Cancer
Issues in Oncology

Gut Microbiome Variations and Colorectal Cancer Risk

Researchers have identified significant variations in the gut microbiome of patients with precancerous colorectal lesions, suggesting a potential correlation between gut bacteria and the onset of precancerous lesions and colorectal cancer, according to new findings presented by Gacesa et al at...

Colorectal Cancer
Issues in Oncology

Tumor Debulking Plus Palliative Chemotherapy May Not Impact Quality of Life in Patients With Metastatic Colorectal Cancer

Intensive local-regional tumor debulking in addition to standard palliative chemotherapy may not impact the overall quality of life of patients with metastatic colorectal cancer, according to a novel study published by Bakkerus et al in JNCCN–Journal of the National Comprehensive Cancer Network....

Colorectal Cancer

Rectal Cancer Managed by Watch-and-Wait Strategy: Validation of Immunoscore Biopsy

In an international validation study reported in the Journal of Clinical Oncology, El Sissy et al found that the Immunoscore biopsy was capable of distinguishing risk of disease recurrence in patients with rectal cancer treated with a watch-and-wait strategy. As stated by the investigators, “No...

Colorectal Cancer

Does Colon Tumor Location Play a Role in Metastasis and Survival?

There have been demonstrated differences in tumor cell metabolism between right-sided and left-sided colorectal tumors, which could explain the differences observed in their clinical behavior, especially in metastatic disease. Now, new research has found that patients with right-sided colorectal...

Colorectal Cancer
Supportive Care

High-Intensity Training May Reduce the Risk of Colorectal Cancer in Patients With Lynch Syndrome

Regular and intense aerobic exercise may be effective at reducing the risk of colorectal cancer in patients with Lynch syndrome by improving the immune system's ability to detect and remove potentially harmful cells, according to a novel study published by Deng et al in Clinical Cancer Research....

Colorectal Cancer

Colorectal Cancer Screening: Major Communication Gap in the Clinical Setting

According to the American Cancer Society, colorectal cancer is the second-leading cause of cancer-related death in the United States. In 2023, the disease is expected to cause an estimated 52,550 deaths. Studies show that receiving a clinician recommendation is the strongest and most consistent...

colorectal cancer

Second- and Third-Line Therapy for Metastatic Colorectal Cancer

This is Part 3 of New Directions in Metastatic Colorectal Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Michael Overman, Laura Goff, and Katrina Pedersen discuss later-line treatment options for metastatic colorectal cancer. The patient is a 64-year-old male with metastatic ascending colon moderately differentiated adenocarcinoma. On CT scan, he has liver, lung, and retroperitoneal lymph node metastases. Molecular testing demonstrates proficient mismatch repair, HER2 IHC negative; a 100-gene next-generation sequencing panel demonstrates KRAS G13D, PIK3CA, CCND2, and ATM mutations. The patient has a good performance status and is initiated on FOLFOXIRI/bevacizumab with partial response, then develops disease progression on fluorouracil/bevacizumab maintenance therapy.   The faculty review the next steps for this patient and the importance of quality-of-life considerations when making treatment decisions. They also discuss the evolving third-line landscape, highlighting the recent SUNLIGHT trial that evaluated the addition of bevacizumab to TAS-102.

colorectal cancer

Second-Line Therapy for Metastatic Colorectal Cancer

This is Part 2 of New Directions in Metastatic Colorectal Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Michael Overman, Laura Goff, and Katrina Pedersen discuss second-line treatment options for metastatic colorectal cancer. The patient is a 46-year-old female with locally advanced, poorly differentiated rectal adenocarcinoma who received neoadjuvant chemoradiation followed by resection, which revealed a ypT4N1 tumor. She received adjuvant FOLFOX for eight cycles; 5 months after completion of therapy, a restaging CT scan revealed more than 10 growing pulmonary nodules, all < 1 cm.   In the conversation that follows, the faculty discuss the many treatment options available in the second-line setting, the factors that impact decision-making, and the emerging role of HER2 amplification/overexpression as an actionable target in metastatic colorectal cancer.

colorectal cancer

Second-Line Therapy for Metastatic Colorectal Cancer

This is Part 2 of New Directions in Metastatic Colorectal Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Michael Overman, Laura Goff, and Katrina Pedersen discuss second-line treatment options for metastatic colorectal cancer. The patient is a 46-year-old female with locally advanced, poorly differentiated rectal adenocarcinoma who received neoadjuvant chemoradiation followed by resection, which revealed a ypT4N1 tumor. She received adjuvant FOLFOX for eight cycles; 5 months after completion of therapy, a restaging CT scan revealed more than 10 growing pulmonary nodules, all < 1 cm.   In the conversation that follows, the faculty discuss the many treatment options available in the second-line setting, the factors that impact decision-making, and the emerging role of HER2 amplification/overexpression as an actionable target in metastatic colorectal cancer.

colorectal cancer

Front-Line Therapy for Metastatic Colorectal Cancer

This is Part 1 of New Directions in Metastatic Colorectal Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Michael Overman, Laura Goff, and Katrina Pedersen discuss front-line treatment options for metastatic colorectal cancer. The patient is a 77-year-old male with a history of resected prostate cancer who developed rectal bleeding. He had a colonoscopy in 2016 that revealed a transverse T3N1 adenocarcinoma that was subsequently resected. After four cycles of FOLFOX, he developed chest pain that led to a CT scan demonstrating left supraclavicular adenopathy. A biopsy is performed, and CT scan shows liver and adrenal metastases.   In the conversation that follows, the faculty discuss the next steps for this patient, the importance of mismatch repair testing in the decision-making process, and the role of monotherapy vs combination therapy.

Colorectal Cancer

Expert Point of View: Peter Paul Yu, MD, FACP, FASCO

ASCO EXPERT Peter Paul Yu, MD, FACP, FASCO, commented on these GALAXY trial findings. He noted the results of this current study and others planned will establish the role of circulating tumor DNA (ctDNA) monitoring for risk of recurrence and guidance for adjuvant therapy. Dr. Yu is...

Colorectal Cancer

Predicting Recurrence in Colorectal Cancer Using Postoperative Circulating Tumor DNA Dynamics

Postoperative molecular residual disease detected by circulating tumor DNA (ctDNA) at 4 weeks after resection has emerged as the strongest prognostic risk factor for disease-free survival in patients with resected colorectal cancer. This finding was observed regardless of BRAF V600E status and...

Colorectal Cancer

Trifluridine/Tipiracil Plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer

On August 2, 2023, the fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, was approved for use with bevacizumab for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based...

Colorectal Cancer

LEAP-017: No Significant Benefit for Lenvatinib Plus Pembrolizumab in Non–MSI-H/dMMR Metastatic Colorectal Cancer

In the final analysis of the phase III LEAP-017 study, the combination of lenvatinib plus pembrolizumab failed to improve outcomes over the standard of care in previously treated patients with metastatic colorectal cancer that lacked high microsatellite instability or mismatch repair deficiency...

Colorectal Cancer
Issues in Oncology

Statins May Be Linked to Lower Risk of Colorectal Cancer in Patients With Ulcerative Colitis

Cholesterol-lowering statins may reduce colorectal cancer incidence and mortality in patients with ulcerative colitis, according to a recent study published by Sun et al in eClinicalMedicine. The findings also suggested that statin use may be associated with a lower risk of all-cause mortality in...

Colorectal Cancer
Immunotherapy

Strategies to Predict Immunotherapy Benefit Among Patients With Advanced Colorectal Cancer

Researchers have identified new strategies to help physicians predict which patients with advanced colorectal cancer may benefit from immunotherapy, according to a recent study published by Saberzadeh-Ardestani et al in Clinical Cancer Research. The findings demonstrate the potential of using...

Colorectal Cancer

Time to Treatment and Survival Among Adults Aged

In a Canadian retrospective cohort study reported in JAMA Network Open, Castelo et al found that a greater interval between date of presentation and treatment initiation was not associated with an increased risk of poorer survival among patients with colorectal cancer diagnosed before age 50. The...

Colorectal Cancer

Avelumab vs Standard Second-Line Chemotherapy in dMMR/MSI Metastatic Colorectal Cancer

In the French phase II SAMCO-PRODIGE 54 trial reported in JAMA Oncology, Julien Taïeb, MD, PhD, and colleagues found that second-line avelumab improved progression-free survival vs standard chemotherapy in patients with mismatch repair­–deficient and/or microsatellite instability (dMMR/MSI)...

Colorectal Cancer

PANDA Trial: First-Line Treatment Regimens for Elderly Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer

In the Italian phase II noncomparative PANDA trial reported in the Journal of Clinical Oncology, Lonardi et al found that regimens adding panitumumab to modified FOLFOX (fluorouracil, leucovorin, and oxaliplatin; mFOLFOX) and to fluorouracil/leucovorin were active in the first-line treatment of...

Colorectal Cancer

Report Highlights Rapid Adoption of Clinical Research Results Into Colon Cancer Chemotherapy Prescribing Patterns

New research published by Ou et al in JNCCN—Journal of the National Comprehensive Cancer Network evaluated how an important analysis on adjuvant chemotherapy for advanced colon cancer impacted prescribing patterns. The IDEA collaboration included more than 12,000 patients with stage III colon...

Advertisement

Advertisement

Advertisement